Electra Therapeutics, Inc. — Form SCHEDULE 13D
Filed September 25, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
Three OrbiMed entities (OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, and OrbiMed Genesis GP LLC) filed a joint Schedule 13D on September 25, 2026, regarding common stock of Electra Therapeutics, Inc. The filing itself contains only the joint filing agreement; specific shareholding percentages, share counts, dollar amounts, and the nature of the stake (passive vs. active intent) are not disclosed in this exhibit excerpt. Carl L. Gordon signed on behalf of the OrbiMed entities.
Why this rating
Schedule 13D filing is mandatory disclosure when 5%+ stake acquired; however, this excerpt shows only procedural joint agreement, not substantive stake details. No material facts about position size, purpose, or business impact are present here.
See more from September 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.